Streptomycin Sulfate

Plague, Chancroid, Tularemia + 13 more
Treatment
13 FDA approvals
20 Active Studies for Streptomycin Sulfate

What is Streptomycin Sulfate

StreptomycinThe Generic name of this drug
Treatment SummaryStreptomycin is an antibiotic made from a soil bacterium called Streptomyces griseus. It was discovered in the 1940s and its antibacterial effects earned its discoverers the Nobel Prize in Medicine. While it was once commonly used to treat tuberculosis, its use has since declined due to the development of resistance. It is now mainly used as a secondary treatment for multi-drug resistant tuberculosis.
Streptomycin Sulfateis the brand name
image of different drug pills on a surface
Streptomycin Sulfate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Streptomycin Sulfate
Streptomycin
1952
2

Approved as Treatment by the FDA

Streptomycin, otherwise called Streptomycin Sulfate, is approved by the FDA for 13 uses which include Tuberculosis (TB) and Plague .
Tuberculosis (TB)
Used to treat Tuberculosis (TB) in combination with Isoniazid
Plague
Tularemia
Pneumonia
Influenza
Urinary Tract Infections
Chancroid
Tuberculosis
Used to treat Tuberculosis (TB) in combination with Isoniazid
Bacterial Infections
Bacteremia
Plague
Granuloma Inguinale
Tularemia

Effectiveness

How Streptomycin Sulfate Affects PatientsStreptomycin is an antibiotic that is used to treat certain bacteria, including Yersinia pestis, Francisella tularensis, Brucella, H. ducreyi, and H. influenza. It is less effective against the bacteria Pseudomonas aeruginosa. Taking streptomycin may lead to hearing loss and vestibular dysfunction, as well as kidney and muscle damage. People taking this drug should be watched carefully for signs of these side effects.
How Streptomycin Sulfate works in the bodyAminoglycosides work to kill bacteria in two ways. First, they bind to bacterial cell membranes, creating holes in and damaging them. This immediately kills the bacteria. Second, they bind to the bacteria's ribosomes and stop proteins from being produced correctly. This eventually leads to the bacteria dying, but takes longer. The aminoglycosides bind to two sites on the ribosome - one near the A site, and one near the 23S rRNA - and stop it from making proteins correctly. As a result, incorrect proteins are made and the cell membrane is damaged, which eventually kills the bacteria.

When to interrupt dosage

The advised dosage of Streptomycin Sulfate is subject to the diagnosed condition, including Tuberculosis (TB), Influenza and Plague. The measure of dosage fluctuates as detailed in the table below, contingent upon the technique of administration (e.g. Liquid - Intramuscular or Liquid).
Condition
Dosage
Administration
Mycobacterium kansasii infection
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular
Acrodynia
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular
Mycobacterium marinum infection
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular
Influenza
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular
Chancroid
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular
Pneumonia
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular
Urinary Tract Infections
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular
Bacterial Infections
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular
Plague
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular
Tuberculosis
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular
Tularemia
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular
Bacteremia
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular
Mycobacterium avium complex infection
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular
Granuloma Inguinale
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular
Disseminated mycobacterium avium complex infection
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular
HIV
1000.0 mg, , 1000.0 mg/mL
, Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Liquid - Intramuscular, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Injection, solution, Injection, solution - Intramuscular

Warnings

Streptomycin Sulfate has two contraindications and must not be taken in coalition with the disorders specified in the table below.Streptomycin Sulfate Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Streptomycin may interact with Pulse Frequency
There are 20 known major drug interactions with Streptomycin Sulfate.
Common Streptomycin Sulfate Drug Interactions
Drug Name
Risk Level
Description
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Streptomycin is combined with Neomycin.
Tenofovir
Major
Streptomycin may increase the nephrotoxic activities of Tenofovir.
Tenofovir alafenamide
Major
Streptomycin may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir disoproxil
Major
Streptomycin may increase the nephrotoxic activities of Tenofovir disoproxil.
Vibrio cholerae CVD 103-HgR strain live antigen
Major
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Streptomycin.
Streptomycin Sulfate Toxicity & Overdose RiskOverdosing on streptomycin can lead to hearing or balance problems, as well as kidney damage. Symptoms of kidney damage may range from mild, such as increased levels of urea in the blood and protein in the urine, to more severe cases of permanent hearing loss and vestibular dysfunction. If a patient has overdosed on streptomycin, their serum concentration can be reduced through dialysis.
image of a doctor in a lab doing drug, clinical research

Streptomycin Sulfate Novel Uses: Which Conditions Have a Clinical Trial Featuring Streptomycin Sulfate?

244 active clinical trials are presently studying the potential of Streptomycin Sulfate in combating Bacterial Infections caused by susceptible bacteria, Mycobacterium avium complex infection and Granuloma Inguinale.
Condition
Clinical Trials
Trial Phases
Granuloma Inguinale
0 Actively Recruiting
Acrodynia
2 Actively Recruiting
Phase 2, Phase 3
Mycobacterium kansasii infection
0 Actively Recruiting
Mycobacterium avium complex infection
1 Actively Recruiting
Phase 2
Tularemia
0 Actively Recruiting
Plague
0 Actively Recruiting
Mycobacterium marinum infection
0 Actively Recruiting
Bacteremia
2 Actively Recruiting
Phase 4, Not Applicable
Disseminated mycobacterium avium complex infection
0 Actively Recruiting
Pneumonia
16 Actively Recruiting
Not Applicable, Early Phase 1, Phase 2
Tuberculosis
2 Actively Recruiting
Phase 3, Phase 2
Chancroid
0 Actively Recruiting
Urinary Tract Infections
7 Actively Recruiting
Not Applicable, Phase 4
Bacterial Infections
0 Actively Recruiting
Influenza
29 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 1, Phase 3
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1

Patient Q&A Section about streptomycin sulfate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is streptomycin sulfate the same as streptomycin?

"The sulfate salt form of streptomycin is an aminoglycoside antibiotic that is derived from Streptomyces griseus and has antibacterial properties."

Answered by AI

What type of antibiotic is streptomycin?

"Streptomycin is an aminoglycoside antibiotic that was first isolated from the bacteria Streptomyces griseus. It is now primarily used as part of the multi-drug treatment of pulmonary tuberculosis. It has additional activity against several aerobic gram-negative bacteria."

Answered by AI

What is streptomycin sulfate used for?

"This antibiotic is used to treat certain types of bacterial infections, however it will not work against infections like colds or the flu. If you have any questions about other purposes for this medicine, ask your health care provider or pharmacist."

Answered by AI

What bacteria is killed by streptomycin?

"Streptomycin is a medication used to treat bacterial infections, including tuberculosis, Mycobacterium avium complex, endocarditis, brucellosis, Burkholderia infection, plague, tularemia, and rat bite fever."

Answered by AI

Clinical Trials for Streptomycin Sulfate

Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+
All Sexes
Houston, TX
Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. For our hypothesis, patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.
Waitlist Available
Has No Placebo
Baylor College of MedicineLarissa Grigoryan, MD, PhD
Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Streptomycin Sulfate clinical trials? We made a collection of clinical trials featuring Streptomycin Sulfate, we think they might fit your search criteria.Go to Trials
Image of National Institutes of Health Clinical Center in Bethesda, United States.

BPL-1357 for Flu

18 - 55
All Sexes
Bethesda, MD
Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it. Current vaccines protect against seasonal flus, but broader vaccines are needed to protect against potential flu pandemics. Objective: To test an experimental flu vaccine. Eligibility: Healthy people aged 18 to 55 years. Design: The study will last 5 to 8 months and has 2 phases, A and B. The study vaccine will be given either as a shot in the arm or as a nasal spray. Participants will receive 1 of 3 combinations: (1) study vaccine in the nose and placebo in the arm; (2) placebo in the nose and study vaccine in the arm; or (3) placebo in the nose and placebo in the arm. A placebo is just like the real vaccine but contains no active ingredients. Phase A: Participants will have 5 clinic visits over 56 days. They will receive a shot and a nasal spray at 2 of the visits, 28 days apart. At each visit, they will have a physical exam, with tests of their blood, urine, and nasal secretions. They will check their temperature at home and record any symptoms for 7 days after each vaccine. Phase B: Participants will stay in the hospital for at least 9 days. They will be infected with a flu virus. They will provide blood, urine, and nasal fluid samples. They will have tests of their heart function. They will remain in the hospital until they test negative for the flu 2 days in a row. They will have 2 follow-up visits, 4 and 8 weeks after leaving the hospital.
Phase 2
Waitlist Available
National Institutes of Health Clinical Center (+1 Sites)Luca T Giurgea, M.D.
Image of Center on Substance Use and Health in San Francisco, United States.

CHAMPION Intervention for Pre-exposure Prophylaxis Adherence

18 - 40
Male
San Francisco, CA
The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are: * To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates. * To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.
Waitlist Available
Has No Placebo
Center on Substance Use and HealthGlenn-Milo Santos, PhD, MPH
Have you considered Streptomycin Sulfate clinical trials? We made a collection of clinical trials featuring Streptomycin Sulfate, we think they might fit your search criteria.Go to Trials
Image of Vanderbilt University Medical Center in Nashville, United States.

High vs. Standard Dose Influenza Vaccines for Flu

18+
All Sexes
Nashville, TN
This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center. Lung transplantation is a life-saving therapy for patients with advanced lung disease, and is also associated with an improvement in quality of life. However, due to the need for life-long immunosuppression to prevent acute cellular rejection and chronic lung allograft dysfunction ("chronic rejection"), lung transplant recipients are at risk for developing major infections. In fact, one-year survival is 85%, with infection being the leading cause of death within the first year post-transplant. We will conduct a follow-up phase II, randomized, double-blind trial to assess the impact of subsequent administration of two doses of HD-IIV compared to two doses of SD-IIV among lung recipients during the early post-transplant period. Demonstration of improved immunogenicity from two doses of HD-IIV over consecutive influenza seasons would provide potential broad benefit in reducing influenza disease and its associated complications in lung transplant recipients. Moreover, studying vaccine immunogenicity and safety in the same participants over consecutive years can provide insight into the influence of immunosuppression levels and allograft aging on vaccine-mediated immune modulation. This proposed study design will contribute significantly to influenza vaccination guidance and policy for the highly vulnerable lung transplant population. This proposed study is designed to address several key knowledge gaps in vaccine-mediated protection of lung transplant recipients against influenza: * Is there increased immunogenicity with administration of one or two doses of HD-IIV or SD-IIV in the subsequent season compared to two doses of HD-IIV or SD-IIV in the first season? * What is the durability of the humoral and cellular immune response between influenza seasons and does two doses of HD-IIV or SD-IIV sustain higher HAI titers compared to two doses of HD-IIV or SD-IIV in the first season? * What is the impact of maintenance immunosuppression levels on influenza vaccine immunogenicity within the same participant? * Will the optimal immunogenic vaccination strategy be associated with an acceptable long-term safety profile over successive influenza seasons, including injection-site and systemic reactions, allosensitization, and organ rejection?
Phase 2
Recruiting
Vanderbilt University Medical CenterNatahsa Halasa, MD, MPH
Image of Altasciences Inc - Kansas City in Overland Park, United States.

VNT-101 for Safety and Tolerability Study

18 - 59
All Sexes
Overland Park, KS
A randomized, double-blind, placebo-controlled Phase 1 study conducted at a single center with approximately 78 healthy adults aged 18-59 years. Part 1 Single Ascending Dose (SAD) will enroll 48 participants into six cohorts (S1-S6) to receive single oral doses of VNT-101 (100-1500 mg) or placebo under fasting or fed (S5 only) conditions. Part 2 Multiple Ascending Dose (MAD) will enroll 30 participants into three cohorts (M1-M3) to receive multiple oral doses of VNT-101 (250-750 mg BID Days 1-5, QD Day 6) or placebo under fasting conditions. Dose escalation in both parts will proceed after Protocol Safety Review Team (PSRT) review. The primary objective for Part 1 is to evaluate the safety and tolerability of single ascending oral (SAD) doses of VNT-101 in healthy adult participants under either fasting or fed conditions. The primary objective for part 2 is to evaluate the safety and tolerability of multiple ascending oral (MAD) doses of VNT-101 in healthy adult participants.
Phase 1
Recruiting
Altasciences Inc - Kansas City
Have you considered Streptomycin Sulfate clinical trials? We made a collection of clinical trials featuring Streptomycin Sulfate, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security